TAT1-DEN

TAT1-DEN is a synthetic, dendritic peptide-based small molecule designed as a proteasome activator and derived from the HIV-1 Tat peptide; it features a branched structure built from multiple triple-lysine fragments joined by 3,5-diaminobenzoic acid, which enhances blood-brain barrier penetration and biological stability. It robustly activates both 20S and 26S human proteasomes in vitro, with maximal activation of 10-fold for 20S and 2.6-fold for 26S proteasomes at nanomolar concentrations. The primary mechanism is stimulation of proteasome peptidase activity, resulting in enhanced proteostasis and the clearance of amyloid precursor protein. TAT1-DEN has demonstrated significant preclinical efficacy in neurodegeneration models, including Alzheimer's disease, by protecting against amyloid toxicity, cognitive decline, and mortality[1][3][5].